Abstract
The Janus kinases (JAKs) enzymes are a family of cytosolic tyrosine kinases that are associated with membrane receptors and play a critical role in the rapid transduction of signals from cell surface to the nucleus. There are four different tyrosine kinases (Tyk2, Jak1, Jak2, Jak3) that share significant structural homology with each other. Binding of cytokines or growth factors to their cognate receptor activate JAK kinases, which in turn mediate the subsequent tyrosine phosphorylation of STAT proteins. Phosphorylated STAT proteins form dimers, translocate to the nucleus, and bind to specific DNA elements to induce or modulate expression of target genes. Aberrant activation of JAK kinases has been implicated in many hematological malignancies and carcinomas. There is also accumulating evidence that constitutive activation of different Jaks and Stats mediate neoplastic transformation and promote abnormal cell proliferation in various malignancies. This review will discuss the role of various Jak-kinase dependent signal transduction pathways in malignancies as well as therapeutic implications of the recent advances in the field.
Keywords: Janus kinase, signal transducer and activator of transcription, suppressors of cytokine signaling, cytokines, signal transduction pathways
Current Enzyme Inhibition
Title: JAK Family of Tyrosine Kinases: Its Functions and Alterations in Human Cancer
Volume: 2 Issue: 2
Author(s): Shahab Uddin, Azhar R. Hussain and Khawla S. Al-Kuraya
Affiliation:
Keywords: Janus kinase, signal transducer and activator of transcription, suppressors of cytokine signaling, cytokines, signal transduction pathways
Abstract: The Janus kinases (JAKs) enzymes are a family of cytosolic tyrosine kinases that are associated with membrane receptors and play a critical role in the rapid transduction of signals from cell surface to the nucleus. There are four different tyrosine kinases (Tyk2, Jak1, Jak2, Jak3) that share significant structural homology with each other. Binding of cytokines or growth factors to their cognate receptor activate JAK kinases, which in turn mediate the subsequent tyrosine phosphorylation of STAT proteins. Phosphorylated STAT proteins form dimers, translocate to the nucleus, and bind to specific DNA elements to induce or modulate expression of target genes. Aberrant activation of JAK kinases has been implicated in many hematological malignancies and carcinomas. There is also accumulating evidence that constitutive activation of different Jaks and Stats mediate neoplastic transformation and promote abnormal cell proliferation in various malignancies. This review will discuss the role of various Jak-kinase dependent signal transduction pathways in malignancies as well as therapeutic implications of the recent advances in the field.
Export Options
About this article
Cite this article as:
Uddin Shahab, Hussain R. Azhar and Al-Kuraya S. Khawla, JAK Family of Tyrosine Kinases: Its Functions and Alterations in Human Cancer, Current Enzyme Inhibition 2006; 2 (2) . https://dx.doi.org/10.2174/157340806776818766
DOI https://dx.doi.org/10.2174/157340806776818766 |
Print ISSN 1573-4080 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6662 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Repurposing Disulfiram as An Anti-Cancer Agent: Updated Review on Literature and Patents
Recent Patents on Anti-Cancer Drug Discovery Stent-Based Delivered Anti-Proliferative Drugs in the Prevention of Coronary Stent Restenosis
Current Medicinal Chemistry - Cardiovascular & Hematological Agents The Possible Use of Terpene Compounds in DC Immunotherapy against Cancer
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Bortezomib and Arsenious Acid Synergistically Inhibit HL-60 Cells Viability in vitro and in vivo
Current Signal Transduction Therapy Mesenchymal Stem Cells in Veterinary Regenerative Therapy: Basic Physiology and Clinical Applications
Current Stem Cell Research & Therapy A Personalized Approach to Systemic Treatment of Unresectable or Metastatic Pancreatic Adenocarcinoma
Current Pharmacogenomics and Personalized Medicine Editorial(Hot Topic:Targeting the Ubiquitin-Proteasome Pathway - Current Perspectives and Future Directions)
Current Pharmaceutical Design c-Myc: Linking Transformation and Genomic Instability
Current Molecular Medicine Physiology of Immune System: Regulation of Stem Cell Survival
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery CypA: A Potential Target of Tumor Radiotherapy and/or Chemotherapy
Current Medicinal Chemistry Clinical Practice of Umbilical Cord Blood Stem Cells in Transplantation and Regenerative Medicine - Prodigious Promise for Imminent Times
Recent Patents on Biotechnology COVID-19 Related Coagulopathy: What is Known Up to Now
Current Medicinal Chemistry microRNA Biogenesis Pathway as a Therapeutic Target for Human Disease and Cancer
Current Pharmaceutical Design Neuronal Generation from Somatic Stem Cells: Current Knowledge and Perspectives on the Treatment of Acquired and Degenerative Central Nervous System Disorders
Current Gene Therapy Nanoparticles in Melanoma
Current Medicinal Chemistry Lifestyle Changes and Surgical Treatment for Hypertension in the Elderly
Cardiovascular & Hematological Agents in Medicinal Chemistry Long Noncoding RNA MALAT1: Insights into its Biogenesis and Implications in Human Disease
Current Pharmaceutical Design Low Dose Chest Computed Tomography, in Identifying Pulmonary Complications in Immunocompromised Patients After Allogeneic Hematopoietic Stem Cell Transplantation
Current Respiratory Medicine Reviews Current Progresses in Metal-based Anticancer Complexes as Mammalian TrxR Inhibitors
Anti-Cancer Agents in Medicinal Chemistry Is Fibroblast Growth Factor Receptor 4 a Suitable Target of Cancer Therapy?
Current Pharmaceutical Design